本帖最后由 老马 于 2012-1-13 21:20 编辑
7 L% I* P/ o4 _3 O! e
7 v. x) e d2 P4 V7 y爱必妥和阿瓦斯丁的比较5 r2 o& g! e, k) R9 Z8 u
2 O2 i9 a6 J8 s: ?9 yhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/) @6 F& Q2 v% A1 j0 }
1 D5 J( X" ~4 f: `
+ R0 D, j/ f1 Z4 G6 Ihttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/# M& D3 Z6 ^8 {; q
==================================================
3 N/ g, A* k) n. w0 X% q1 rOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2 k+ ~, e- B; M9 o, c! I ~Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
( G. f( R' C. S" @* aResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.- _; s4 i" [# w; y: F3 k& G
|